Cubist Pharms Llc Company Profile

✉ Email this page to a colleague

CUBIST PHARMS LLC has six approved drugs.

There are twenty-nine US patents protecting CUBIST PHARMS LLC drugs.

There are three hundred and forty-two patent family members on CUBIST PHARMS LLC drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011	AB	RX	Yes	Yes	7,378,508*PED	⤷ Sign Up			Y	⤷ Sign Up
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	7,378,508*PED	⤷ Sign Up			Y	⤷ Sign Up
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	11,278,622	⤷ Sign Up				⤷ Sign Up
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	TABLET;ORAL	205435-001	Jun 20, 2014		RX	Yes	Yes	9,624,250	⤷ Sign Up	Y	Y		⤷ Sign Up
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	RE39071	⤷ Sign Up
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	5,912,226	⤷ Sign Up
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	5,912,226	⤷ Sign Up
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	6,468,967	⤷ Sign Up
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	RE39071	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2008-11-19
➤ Subscribe	Tablets	200 mg	➤ Subscribe	2015-05-27

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Russian Federation	2011136537	⤷ Sign Up
Singapore	10201407724Y	⤷ Sign Up
Portugal	2305245	⤷ Sign Up
Argentina	079127	⤷ Sign Up
World Intellectual Property Organization (WIPO)	2005058886	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1556389	SPC/GB16/002	United Kingdom	⤷ Sign Up	PRODUCT NAME: CEFTOLOZANE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PARTICULAR A SULFURIC ACID SALT.; REGISTERED: UK EU/1/15/1032 20150922
1115417	CA 2006 00018	Denmark	⤷ Sign Up	PRODUCT NAME: DAPTOMYCIN
1699784	1590047-5	Sweden	⤷ Sign Up	PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/991 20150325
1539977	C01539977/01	Switzerland	⤷ Sign Up	FUSION; FORMER OWNER: MERCK SHARP AND DOHME CORP., US
1539977	SPC/GB15/020	United Kingdom	⤷ Sign Up	PRODUCT NAME: FIDAXOMICIN; REGISTERED: UK EU/1/11/733/001 20111207; UK EU/1/11/733/002 20111207; UK EU/1/11/733/003 20111207; UK EU/1/11/733/004 20111207
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.